What question did this study set out to answer?

To evaluate the long-term progression-free survival, safety, and subgroup outcomes of ibrutinib regimens versus bendamustine plus rituximab in older patients with previously untreated chronic lymphocytic leukemia.

January 12, 2024BloodOpen Access

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

View Full Paper

Ask AI

Bookmark

Authors

JWJennifer A. Woyach GBGabriela Perez Burbano ARAmy S. Ruppert

Discussion

Member takes

Overview

Randomized trial reveals superior progression-free survival with ibrutinib in older adults with untreated chronic lymphocytic leukemia, highlighting durable benefits in high-risk genomic subgroups.

Key Points

To evaluate the long-term progression-free survival, safety, and subgroup outcomes of ibrutinib regimens versus bendamustine plus rituximab in older patients with previously untreated chronic lymphocytic leukemia.
Phase 3 randomized trial (A041202, NCT01886872) evaluating bendamustine plus rituximab (BR), ibrutinib monotherapy, and ibrutinib plus rituximab (IR) in older adults with untreated chronic lymphocytic leukemia.
Outcomes including progression-free survival, overall survival, adverse events, and efficacy across genomic subgroups were assessed over a median follow-up of 55 months.
Median progression-free survival was 44 months (95% CI, 38–54) with BR and not reached in either ibrutinib-containing arm, with 48-month progression-free survival rates of 47% for BR versus 76% for both ibrutinib and IR.
Progression-free survival benefits with ibrutinib were sustained across high-risk genomic subsets, including TP53 abnormalities, del(11q), and complex karyotypes, with no difference observed in overall survival.
Adverse events in ibrutinib-treated patients included higher incidences of atrial fibrillation (18% vs. 3%) and all-grade hypertension (55% vs. 27%) compared to BR.

Cite This Study

Woyach et al. (2024) studied this question.

synapsesocial.com/papers/6a82cfb62403b1e95c470433 https://doi.org/10.1182/blood.2023021959

View Full Paper

Ask AI

Bookmark

January 12, 2024BloodOpen Access

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

View Full Paper

Ask AI

Bookmark

Authors

JWJennifer A. Woyach GBGabriela Perez Burbano ARAmy S. Ruppert

Discussion

Member takes

Overview

Randomized trial reveals superior progression-free survival with ibrutinib in older adults with untreated chronic lymphocytic leukemia, highlighting durable benefits in high-risk genomic subgroups.

Key Points

To evaluate the long-term progression-free survival, safety, and subgroup outcomes of ibrutinib regimens versus bendamustine plus rituximab in older patients with previously untreated chronic lymphocytic leukemia.
Phase 3 randomized trial (A041202, NCT01886872) evaluating bendamustine plus rituximab (BR), ibrutinib monotherapy, and ibrutinib plus rituximab (IR) in older adults with untreated chronic lymphocytic leukemia.
Outcomes including progression-free survival, overall survival, adverse events, and efficacy across genomic subgroups were assessed over a median follow-up of 55 months.
Median progression-free survival was 44 months (95% CI, 38–54) with BR and not reached in either ibrutinib-containing arm, with 48-month progression-free survival rates of 47% for BR versus 76% for both ibrutinib and IR.
Progression-free survival benefits with ibrutinib were sustained across high-risk genomic subsets, including TP53 abnormalities, del(11q), and complex karyotypes, with no difference observed in overall survival.
Adverse events in ibrutinib-treated patients included higher incidences of atrial fibrillation (18% vs. 3%) and all-grade hypertension (55% vs. 27%) compared to BR.

Cite This Study

Woyach et al. (2024) studied this question.

synapsesocial.com/papers/6a82cfb62403b1e95c470433 https://doi.org/10.1182/blood.2023021959

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark